Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ociperlimab, a humanized IgG1 anti-TIGIT antibody, exhibits high affinity for the extracellular domain of human TIGIT, with a dissociation constant (K_D) of 0.135 nM. It effectively inhibits the interaction between TIGIT and its ligands PVR or PVR-L2, and is utilized in cancer research [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Ociperlimab, a humanized IgG1 anti-TIGIT antibody, exhibits high affinity for the extracellular domain of human TIGIT, with a dissociation constant (K_D) of 0.135 nM. It effectively inhibits the interaction between TIGIT and its ligands PVR or PVR-L2, and is utilized in cancer research [1] [2]. |
In vitro | Ociperlimab (BGB-A1217; 0-10 μg/mL) enhances the secretion of IFN-γ by cytomegalovirus-specific T cells [1]. At concentrations of 1-1000 ng/mL, ociperlimab activates natural killer cells and monocytes in an Fc-dependent manner [1]. Additionally, ociperlimab removes TIGIT from the surface of T cells through Fc-dependent endocytosis in vitro [1]. |
In vivo | Ociperlimab (BGB-A1217; doses of 3 and 10 mg/kg; administered intraperitoneally) elicits antitumor efficacy through an Fc-dependent mechanism in CT26 WT and MC38 tumor-bearing humanized TIGIT-knockin mice [1]. |
Synonyms | BGB-A1217 |
Molecular Weight | N/A |
CAS No. | 2342597-93-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ociperlimab 2342597-93-5 BGB-A-1217 BGB-A 1217 BGB-A1217 inhibitor inhibit